CeriBell (NASDAQ:CBLL) Share Price Breaks Above Fifty Day Moving Average - Should You Sell?

CeriBell logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • CeriBell shares rose above their 50-day moving average, trading at $25.75 versus the average of $25.66; the 200-day average is $21.15.
  • Analysts give the stock a consensus “Moderate Buy” rating and an average price target of $31.25, though recommendations range from Strong Buy to Sell.
  • Latest quarterly results showed an EPS loss of $0.55, missing estimates, while revenue of $29.34 million topped expectations. Insiders have sold 139,859 shares worth about $3.55 million over the past 90 days.
  • Interested in CeriBell? Here are five stocks we like better.

CeriBell, Inc. (NASDAQ:CBLL - Get Free Report)'s stock price passed above its fifty day moving average during trading on Thursday. The stock has a fifty day moving average of $25.66 and traded as high as $26.00. CeriBell shares last traded at $25.75, with a volume of 537,237 shares changing hands.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Raymond James Financial reaffirmed a "strong-buy" rating and issued a $29.00 price target on shares of CeriBell in a research note on Thursday, September 3rd. Canaccord Genuity Group upped their target price on shares of CeriBell from $26.00 to $33.00 and gave the company a "buy" rating in a research note on Wednesday, November 4th. Weiss Ratings raised CeriBell from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Friday, October 16th. Barclays upgraded CeriBell to a "neutral" rating in a report on Tuesday, August 18th. Finally, BTIG Research restated a "buy" rating on shares of CeriBell in a report on Wednesday, November 4th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, CeriBell currently has an average rating of "Moderate Buy" and an average price target of $31.25.

Check Out Our Latest Analysis on CeriBell

CeriBell Stock Performance

The stock has a fifty day simple moving average of $25.66 and a 200-day simple moving average of $21.15. The stock has a market cap of $1.00 billion, a P/E ratio of -13.27 and a beta of 0.86. The company has a debt-to-equity ratio of 0.17, a quick ratio of 7.79 and a current ratio of 8.18.

CeriBell (NASDAQ:CBLL - Get Free Report) last issued its quarterly earnings results on Tuesday, November 3rd. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.04). The business had revenue of $29.34 million for the quarter, compared to the consensus estimate of $29.18 million. CeriBell had a negative return on equity of 52.59% and a negative net margin of 67.96%. On average, equities analysts expect that CeriBell, Inc. will post -2.05 earnings per share for the current year.

Insider Activity

In related news, VP David Foehr sold 9,255 shares of the company's stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $24.25, for a total transaction of $224,433.75. Following the transaction, the vice president directly owned 34,144 shares of the company's stock, valued at approximately $827,992. This represents a 21.33% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director William W. Burke sold 18,000 shares of CeriBell stock in a transaction dated Thursday, November 12th. The shares were sold at an average price of $26.64, for a total transaction of $479,520.00. Following the transaction, the director owned 23,022 shares of the company's stock, valued at $613,306.08. This represents a 43.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 139,859 shares of company stock worth $3,554,775. Insiders own 17.70% of the company's stock.

Institutional Trading of CeriBell

Hedge funds have recently bought and sold shares of the business. BlackRock Inc. bought a new stake in shares of CeriBell in the 2nd quarter worth approximately $37,657,000. KCM Capital Inc grew its holdings in CeriBell by 40.0% during the first quarter. KCM Capital Inc now owns 1,400,000 shares of the company's stock valued at $25,662,000 after purchasing an additional 400,000 shares during the period. Bank of New York Mellon Corp purchased a new stake in CeriBell in the second quarter worth $17,437,000. TimesSquare Capital Management LLC purchased a new stake in CeriBell in the second quarter worth $15,182,000. Finally, Goldman Sachs Group Inc. raised its stake in shares of CeriBell by 25.1% in the third quarter. Goldman Sachs Group Inc. now owns 350,570 shares of the company's stock valued at $8,550,000 after buying an additional 70,261 shares during the period.

About CeriBell

(Get Free Report)

Ceribell, Inc. develops neurodiagnostic technology for detecting and monitoring seizures. Its products are designed to make electroencephalography (EEG) more accessible in emergency departments and intensive care units, where timely assessment can be important and conventional EEG services may not be readily available. The company's Ceribell point-of-care EEG system combines a headband with electrodes, a portable recorder and software for viewing and analyzing EEG data. Its Clarity algorithm is designed to help clinicians identify patterns associated with seizure activity, while the system supports remote review by specialists.

Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in CeriBell Right Now?

Before you consider CeriBell, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CeriBell wasn't on the list.

While CeriBell currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines